Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

NCT00943670 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

BIOLOGICAL: pertuzumab
BIOLOGICAL: Trastuzumab emtansine [Kadcyla]

Sponsor

Genentech, Inc.